Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
X4 Pharmaceuticals, Inc incurred term loan of $32.5 million with Hercules Capital, Inc. at per annum rate equal to the greater of (i) 3.15% plus the Wall Street Journal pr maturing April 1, 2026.
- Instrument
- term loan
- Principal
- $32.5 million
- Counterparty
- Hercules Capital, Inc.
- Rate
- per annum rate equal to the greater of (i) 3.15% plus the Wall Street Journal pr
- Maturity
- April 1, 2026
- Event
- incurrence
Exact text from the filing
On January 6, 2023, X4 Pharmaceuticals, Inc. (the “Company”) and its subsidiary, X4 Therapeutics, Inc. (together with the Company, the “Borrowers”), entered into a Second Amended and Restated Loan and Security Agreement (the “Second A&R Loan Agreement”) with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders (collectively, “Hercules”), which provides for a term loan of $32.5 million (the “Term Loan”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
X4 Pharmaceuticals, Inc amended Second Amended and Restated Loan and Security Agreement with Hercules Capital, Inc., Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1 valued at $32.5 million (effective 2023-01-06).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc., Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1
- Value
- $32.5 million
- Effective
- 2023-01-06
Exact text from the filing
On January 6, 2023, X4 Pharmaceuticals, Inc. (the “Company”) and its subsidiary, X4 Therapeutics, Inc. (together with the Company, the “Borrowers”), entered into a Second Amended and Restated Loan and Security Agreement (the “Second A&R Loan Agreement”) with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders (collectively, “Hercules”), which provides for a term loan of $32.5 million (the “Term Loan”).
View on SEC.gov